Search | Clinical Trials Finder

Conditions: Influenza Vaccines, Aged
Interventions: MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV); Biological
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 65 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more

Conditions: Anthrax
Interventions: Anthrax, Alhdryogel or PBS; Biological
Lead sponsor: DynPort Vaccine Company LLC, A GDIT Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Genital Herpes Simplex Type 2
Interventions: VCL-HB01, VCL-HM01, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Infectious Disease
Interventions: Nozin® Nasal Sanitizer®, Placebo; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS), pH 7.0; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Skin Diseases, Infectious
Interventions: sterile Phosphate Buffer Saline, SGW13; Other
Lead sponsor: Center for Innovation and Research Organization; Network
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Metastatic Breast Cancer
Interventions: OPT-822/OPT-821(30 μg/100 μg), Phosphate Buffer Saline (PBS), Cyclophosphamide; Biological · Drug
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 13
States / cities: Birmingham, Alabama • Fullerton, California • La Jolla, California + 10 more

Conditions: Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions: iSCIB1+, Nivolumab & Ipilimumab, Placebo; Biological · Drug · Other
Lead sponsor: Scancell Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Immunologic Tests
Interventions: Serum samples; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 64 Years
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS-CoV-2
Interventions: Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose; Drug · Biological
Lead sponsor: Sean Liu; Other
Eligibility: 18 Years to 59 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Tuberculosis
Interventions: BCG strain Connaught, BCG strain Danish, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 with Matrix M-2, GEN-003, Placebo; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cincinnati, Ohio + 4 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Anemia, Sickle Cell
Interventions: Rivipansel, Placebo; Drug · Other
Lead sponsor: Biossil Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 126
States / cities: Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more

Conditions: Healthy Adult Volunteers
Interventions: NB-1008, Control; Biological · Other
Lead sponsor: NanoBio Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions: Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza
Interventions: VCL-IPM1, VCL-IPT1, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Stony Brook, New York

Conditions: Influenza
Interventions: DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Search by objective public record fields.

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

H5N1 Mix and Match With AS03

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Effect of an Antiseptic Solution on the Skin Microbiome

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

2013/2017 H7N9 Prime-Boost Interval

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone